Material Event (Form 8-K)

Item 8.01 - Other Events

Telomir Pharmaceuticals Reports New Cellular Data Supporting an Epigenetic Modulation Mechanism Implicated in Cancer and Aging

Cellular findings show Telomir-Zn modulates intracellular metal balance linked to oxidative stress, mitochondrial dysfunction, DNA methylation instability, and genomic integrity-without relying on cytotoxic mechanisms.

On February 5, 2026, Telomir Pharmaceuticals, Inc. (the "Company") reported new findings from preclinical cellular studies evaluating its lead investigational compound, Telomir-1, in the form of Telomir-Zn.

In these studies, done in collaboration with Smart Assays Biotechnologies, Telomir-Zn was shown to induce a rapid and coordinated intracellular redistribution of metals, characterized by increased intracellular zinc levels and a reciprocal reduction in labile ferrous iron. The effects were dose-dependent, detected within approximately 30 minutes of exposure, sustained over a two-hour period, and observed without loss of cell confluence or viability in the evaluated cellular models. Zinc accumulation and iron reduction occurred over similar concentration ranges and timeframes, supporting a coordinated intracellular process rather than independent or nonspecific metal effects.

Iron and zinc play fundamentally different roles in cellular biology. Excess labile iron is redox-active and can drive reactive oxygen species generation, contributing to mitochondrial damage, DNA instability, and dysregulation of metal-dependent epigenetic enzymes. Zinc, by contrast, is redox-inert and supports chromatin structure, DNA repair, antioxidant defenses, and proper regulation of epigenetic processes. The observed simultaneous reduction of redox-active iron and enrichment of intracellular zinc suggests a metal-exchange process that may reduce oxidative stress while stabilizing epigenetic and mitochondrial function.

These findings are significant because dysregulated metal balance, oxidative stress, and epigenetic instability are shared upstream drivers of both cancer biology and age-related cellular decline. By demonstrating coordinated zinc-iron modulation, the reported data support a mechanism that acts at a foundational biological level rather than targeting downstream disease manifestations.

The Company also reported that it continues to advance a portfolio of ongoing and completed preclinical research programs, including studies in triple-negative breast cancer models and longevity-focused models. Based on data generated from completed studies, manuscript submissions to peer-reviewed journals have been initiated, while additional data continue to be generated from ongoing preclinical studies.

In addition, the Company reported that it is finalizing IND-enabling activities and currently plans to submit an Investigational New Drug application in the first quarter of 2026.